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Abstract
Pregnancy is a complex of metabolic, physiological, biochemical, and immunological 
changes in women’s body, usually reversible after delivery in normal pregnancy. Gestational 
diabetes mellitus (GDM) is defined as “any degree of glucose intolerance with onset or 
first recognition during the current pregnancy.” The etiology of the GDM is multifacto-
rial and not sufficiently elucidated. The overweight and obesity during prepregnancy and 
pregnancy are one of the main modifiable risk factors of GDM. Maternal obesity increases 
the risk of a number of pregnancy complications, adverse pregnancy outcome for mother 
and child, and related chronic conditions in women. The obesity prevalence is the greatest 
among children of obese mothers, and an independent association between maternal body 
mass index and offspring adiposity and insulin resistance exists. Although the underlying 
mechanism remains unclear, available evidence suggests that GDM pathogenesis is based 
on relatively diminished insulin secretion coupled with pregnancy-induced insulin resis-
tance. Recent findings provide data that higher BMI leads to decreased insulin sensitivity 
and higher degree of insulin resistance and contributes to GDM development.
Keywords: gestational diabetes mellitus, pregnancy, body mass index, homeostasis 
model assessment, quantitative insulin sensitivity check index
1. Introduction
Normal pregnancy has typical significant changes in maternal insulin resistance and hyper-
insulinemia together with progressively increasing insulin secretion during gestation. The 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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distribution, and reproduction in any medium, provided the original work is properly cited.
glucose metabolism regulation during pregnancy has a complex characteristic. The placenta 
plays a critical role in the delivery of nutrients and the regulation of normal fetal growth. It has 
a metabolic and endocrine function, and produces cytokines that influence on the fetal growth. 
Gestational diabetes mellitus (GDM) is a serious complication of normal pregnancy. It is 
defined as “any degree of glucose intolerance with onset or first recognition during the current 
pregnancy.” The global prevalence ranges between 1 and 14%, depending on the population 
studied and the diagnostic tests applied. GDM represents nearly 90% of all pregnancies with 
diabetes [1] and is one of the most common complications with risks for the mother and fetus. 
GDM is not only associated with adverse pregnancy outcomes such as macrosomia, shoulder 
dystocia, stillbirth, hypertension, and other obstetric complications [2, 3], but is also a strong 
predictor of impaired glucose tolerance and transitioning to overt type 2 diabetes mellitus 
(T2DM) postpartum [4]. Although most of the women with previous GDM return to normal 
glucose tolerance after delivery, both GDM patients and their offspring are at a greater risk of 
developing T2DM later [5]. The exact cellular mechanisms involved in GDM development are 
not yet completely understood. Growing data provide evidence for common pathogenesis of 
different diabetes forms as a result of a progressive β-cell dysfunction, inadequacy to secrete 
insulin, and insulin resistance in peripheral tissues leading to hyperglycemia. Pancreatic β-cell 
dysfunction is one of the main pathogenetic GDM mechanisms [6, 7]. Although this defect 
likely precedes the pregnancy [8], first it is detected clinically as insufficient β-cell compensa-
tion of insulin resistance in late pregnancy. GDM occurs if pancreatic β-cells are unable to 
face the increased insulin demand during pregnancy with elevated glucagon-like peptide 1 
(GLP-1) confirming the abnormal insulin secretion [9]. The β-cell defect in GDM women is still 
present in the postpartum period [10]. Pregnancy is a diabetogenic condition. Many causes 
are suggestive for insulin resistance or decreased maternal insulin sensitivity. Pregnancy is 
normally characterized by progressive insulin resistance with beginning near mid-pregnancy 
and progression during the third trimester to levels approximating the insulin resistance 
typical for type 2 diabetes mellitus (T2DM) [11]. Firstly, Ryan et al. [12], using the euglycemic 
clamp technique, demonstrate decrease in insulin sensitivity with a state of insulin resistance 
in pregnancy being more marked in gestational-onset diabetic women in comparison of non-
diabetic control group in late pregnancy. These alterations could be due to placental factors, 
progesterone, and estrogen, having insulin-antagonistic effects [12]. It seems that gestational 
diabetes and T2DM are the faces of one and the same disease. Women who develop GDM 
probably have reduced insulin secretion and/or chronic insulin resistance before pregnancy 
[13, 14] with a substantially increased risk of developing T2DM later [15]. GDM is the most 
common pregnancy metabolic disorder with an increasing prevalence ranging from less than 
1 to 28% [16–18] that parallels the worldwide epidemic of T2DM [19]. The frequency of occur-
rence depends on diagnostic methods, ethnicity, and body composition [20]. Some ethnic 
groups have been long associated with an increased risk of GDM, and the prevalence seems 
particularly higher among women from South Asia and South East Asia than from Caucasian, 
African-American, and Hispanic communities [21]. Several pathophysiological mechanisms 
for GDM development have been proposed as metabolic, inflammatory, autoimmune, and 
genetic ones with various biologic and molecular pathways for regulation of glucose levels 
involved. During pregnancy, fine balance between pro -and anti-inflammatory cytokines, 
necessary for the normal development, exists [22]. In particular, GDM seems to be linked to 
downregulation of adiponectin and anti-inflammatory cytokines, and to upregulation of adi-
pokines as leptin and pro-inflammatory cytokines, implicated in insulin resistance [22].
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2. Obesity and risk of GDM
2.1. Obesity before pregnancy
The etiology of GDM is multifactorial and not sufficiently elucidated. The overweight, obe-
sity during prepregnancy and pregnancy, excessive gestational weight gain, excessive cen-
tral body fat deposition, are among the main modifiable risk factors of GDM and contribute 
significantly to risk of pregnancy complications. Obesity and diabetes constitute worldwide 
threats to the public health [23] and health care systems and economies [24]. Obesity is a 
chronic inflammatory state. Pregnancy and especially GDM are associated with elevation 
in inflammatory markers thus the heightened inflammatory response may play a substan-
tial role in pregnancy complications [22]. Obesity prevalence has been continuously grown, 
particularly in lower and middle-income countries, but in both, developed and developing 
countries, more women are obese at conception, and young women at fertile age are at high 
risk of excess weight gain driving obesity and related reproductive and metabolic complica-
tions [25]. The obesity in worldwide is epidemic. The number of individuals with obesity 
doubled between 1980 and 2014. Moreover, in 2014, over 1.9 billion adults (18+ years) were 
overweight, with over 600 million being obese [26]. Accumulating epidemiological data con-
firm that maternal obesity has short- and long-term implications for women and babies, with 
a threefold increased risk of GDM [27], large for gestational age babies [28], also increased 
probability of macrosomia and childhood obesity [29–31], and even of fetal death, stillbirth, 
and infant death [32]. GDM brings a sevenfold higher risk for future development of T2DM 
[15]. Excessive adiposity and weight gain are well-documented risk factors of type 2 diabetes 
in the general population [33–35]. Women who develop GDM are more likely to be over-
weight or obese at the time of the diagnosis in comparison to the general population. A larger 
part of them develop incident of overweight or obesity in later life. Women with a history of 
GDM are usually advised to control their weight after delivery [36].
2.2. Excessive gestational weight gain as risk factor for GDM
An excess body weight is a major health issue worldwide as the sixth significant risk factor 
contributing to disease, and the increased obesity level may result in a decline of life expec-
tancy in the future [37]. The body mass index (BMI), or Quetelet index, is used to assess the 
degree of obesity/human body fat based on an individual’s weight and height [38]. However, 
BMI values may have different connotations in individuals with diverse ethnic background, 
short/tall stature, or varied muscle mass, and do not reflect the regional distribution of fat in 
the body, i.e., subcutaneous versus visceral/central [39]. Both prepregnancy BMI and weight 
gain during pregnancy are positively associated with gestational insulin resistance [40, 41], 
with obesity being a risk factor for GDM [42] and increased risk of adverse maternal and 
perinatal outcomes [43]. In addition to high risk of GDM, excessive gestational weight gain 
(EGWG) and obesity in prepregnancy have further adverse risks of preeclampsia, eclampsia, 
cesarean delivery, macrosomia, etc. [44–48]. Because of increasing living standards, EGWG 
prevalence is higher than ever before with approximately 40% of pregnant women gain-
ing more weight than is recommended [48]. These two factors—high prepregnancy BMI 
and EGWG—have been reported as well-established risk for adverse pregnancy outcomes 
[49–54]. Large studies, including different ethnic women in western countries, determine 
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increased risk for macrosomia in parallel with increasing EGWG in all prepregnancy BMI cat-
egories, and the risk varies in relation to degree of BMI [55–58]. Moreover, more underlined 
risk of macrosomia in overweight and obese before pregnancy women and in those who gain 
excessive weight during pregnancy has been proved [59]. Women with previous pregnancies 
complicated by GDM are at an increased risk of developing T2DM in the postpartum [15]. 
A meta-analysis evaluates 28 studies including women with previous GDM, with follow-up 
ranging between 6 weeks and 28 years after the end of pregnancy, and it reveals rates of 
T2DM between 2.6 and 70%, depending on ethnicity, diagnostic criteria, and the follow-up 
period [60]. Prepregnancy obesity and excessive weight gain from prepregnancy to postpar-
tum increase postpartum diabetes and prediabetes risks among GDM women [61]. Women, 
failing to lose weight postpartum, are with a higher risk of subsequent long-term obesity 
[62]. The recent meta-analysis shows 18% increase in risk of diabetes per unit increase in 
BMI [63], and every kilogram of weight gain increases by 7% the risk of diabetes [64]. Several 
studies have indicated that body fat distribution, dependent on ethnicity, has a larger effect 
than general obesity in predicting the risk of diabetes [65, 66]. Asians are with smaller frames 
and lower body fat distribution than white Europeans for the same BMI [67]. In comparison 
to Europeans, Chinese, and South Asians have more abdominal adipose tissue, especially 
visceral adipose tissue [68]. In this regard, waist circumference (WC) is a simple and valid 
index to assess abdominal fat and has been proved to be an independent predictor of T2DM 
[69, 70]. In Caucasian women, WC is also an important predictor of GDM [71].
2.3. Obesity and adipose tissue
In the last decade, abundant data have indicated that adipose tissue is not just an energy 
storage depot but rather a metabolically active tissue [72]. Adipose tissue is considered to be 
an important and active organ for maintenance of systemic homeostasis through a complex 
network of auto-, para-, and endocrine cross talks to other tissues and organs [73] mediat-
ing the development of obesity and related diseases. During obesity, the number and size 
of adipocytes are increased [74]. Studies of adipocytes from women in different trimesters 
reveal alterations in lipolytic activity that promote maternal fat accumulation in early preg-
nancy and enhance fat mobilization in late pregnancy [75]. Hypertrophy of adipocytes can 
impair the functions of adipose tissue in association with excess amount of adiposity and 
leading to a dysregulated secretory profile [76]. Obesity in pregnancy has intense effects, 
causing systemic inflammation. Maternal obesity and GDM may be associated with a state 
of chronic, low-grade inflammation, referred as “meta-inflammation,” opposite to an acute 
inflammatory response [77], or metabolically induced inflammation. Meta-inflammation is 
distinct from an acute pro-inflammatory response and is triggered primarily by metabolites 
and nutrients, leading to systemic insulin resistance [78]. The base of this chronic low-grade 
inflammation is a production of pro-inflammatory cytokines by adipocytes in obesity [79]. 
This elevation of circulating pro-inflammatory cytokines, originated from adipose tissue, may 
induce increased inflammatory cytokine secretion by the placenta and alter placental function 
[80]. During pregnancy, similar to gestational age, the size of the placenta is also in progress. 
The levels of pregnancy-associated hormones estrogen, progesterone, cortisol, and placental 
lactogen in the maternal circulation are elevated [81, 82] accompanied by an increasing insulin 
resistance. A healthy pregnancy outcome is highly reliant on tight physiological regulation 
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largely orchestrated by the placenta, an extremely complex and multifunctional materno-fetal 
organ [83]. The placenta like a transient endocrine organ with a secretion of various hormones 
and cytokines, affecting both maternal and fetal metabolism, plays a major role in the initiation 
and preservation of pregnancy. Maternal obesity significantly impacts the endocrine func-
tion of the placenta. Obese pregnancies have a dysregulated maternal cytokine profile with 
considerable rise in pro-inflammatory cytokines [84, 85]. Furthermore, such over expression 
of pro-inflammatory cytokines is also observable in GDM placenta. This alteration in normal 
secretion of adipocytokines is involved as an essential factor in GDM development [86–89].
2.4. Adipose tissue and adipokines in normal pregnancy and in pregnancy  
with GDM
Adipokines, secreted from adipose tissue, are involved in a wide spectrum of biological pro-
cesses, including regulation of energy homeostasis, adipocyte proliferation and differentia-
tion, inflammation, angiogenesis and regulation of coagulation, and vascular function [90–92]. 
Adipokines act locally in adipose tissue (auto- and paracrine manners), but they also medi-
ate via the circulation the cross talks between adipose tissue and other key metabolic organs 
(endocrine manner). Some adipokines, such as leptin and adiponectin, are adipocyte specific, 
while others, like pro-inflammatory cytokines, to a higher degree are secreted by the nonfat 
cells in adipose tissue [76]. In obesity, dysregulation of pro- and anti-inflammatory cytokines 
released from adipose tissue is in the base of the chronic low-grade systemic inflammation as 
that leads to development of metabolic and cardiovascular disorders [93, 94] and promotes 
insulin resistance or GDM. Adipose tissue produces adipocytokines, including leptin, adi-
ponectin, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), as well as the recently 
discovered resistin, visfatin, and apelin [95, 96]. A study finds the circulatory levels of IL-6, 
interleukin-8 (IL-8), interleukin-1β (IL-1β), TNFα, and C-reactive protein (CRP) are higher in 
overweight and obese pregnant women, relatively to normal weight women during pregnancy 
and postpartum [97]. The expression of pro-inflammatory cytokines has also been reported 
to be dysregulated in the development of GDM introducing an altered cytokine profile in 
hyperglycemic pregnancies [98, 99]. These effects are all related to regulation of insulin resis-
tance. Higher circulatory levels of CRP, IL-6, monocyte chemoattractant protein-1 (MCP-1), 
and interleukin-1 (IL-1) receptor antagonist (IL-1Ra) are significantly associated with maternal 
adiposity [100]. Increased circulation levels of pro-inflammatory cytokines, IL-6, TNFα, leptin, 
and decreased levels of adiponectin and anti-inflammatory markers such as interleukin-4 (IL-4) 
and interleukin-10 (IL-10) are seen in GDM pregnancies in comparison to normal pregnan-
cies, regardless of BMI [99]. The elevated circulating levels of IL-6 and TNFα in maternal 
blood are consistently observed in maternal obesity as well as in GDM, in the presence or 
absence of obesity [101–103]. TNFα and leptin have been suggested as the strongest predictors 
of pregnancy-associated insulin resistance [104, 105]. Together with increased levels of serum 
cortisol, interleukins, and other factors, they can interrupt the insulin signaling pathway and 
lead to insulin resistance during normal pregnancy [104]. Additionally, TNFα has been estab-
lished as the most significant predictor of pregnancy-induced insulin resistance, with higher 
synthesis and releasing by the placenta in comparison to IL-6 or IL-8 [106]. Hence, TNF-α 
is more likely to exert crucial effects on IR during pregnancy. Although the leptin is pro-
duced mainly by adipocytes, there is strong evidence that the placenta, rather than maternal 
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adipose tissue, contributes to the rise in maternal leptin concentrations during pregnancy 
[107]. Pregnancy is considered as a leptin-resistant state, but the results on circulating leptin 
levels in GDM are controversial. However, most studies have shown increased leptin in GDM 
[108–110]. Adiponectin, anti-inflammatory factor, is considered to have beneficial effects on 
insulin sensitivity and anti-inflammatory activities [99]. TNF-α, leptin, and adiponectin are 
produced by placenta [111, 112] and releasing into the maternal circulation contributes to the 
rise in maternal TNF-α and leptin concentrations during pregnancy [104], more pronounced in 
GDM than in normal pregnancy [99]. Increased circulating concentrations of TNF-α enhance 
leptin production, opposite, leptin increases the production of TNF-α and IL-6 by monocytes 
[113] and stimulates the production of CC chemokine ligands (CCL) [114]. Except this, TNF-α 
and other pro-inflammatory mediators suppress the production of adiponectin by adipocytes 
[115]. Something more, some studies find a significant positive correlation between BMI val-
ues and levels of TNF-α and leptin, and an inverse correlation between BMI and adiponectin 
levels in GDM [108, 116–118]. The increased secretion of pro-inflammatory cytokines, the rela-
tive hypoxia, and cell death due to hypertrophic adipocytes promote a high infiltration rate 
of monocytes into visceral adipose tissue and activation of macrophages [119]. In general, 
the increase in release of pro-inflammatory cytokines, infiltration of macrophages, as well 
as relationship between hypertrophic growth of adipose tissue and inflammation lead to the 
development of insulin resistance [120] and β-cell failure [121, 122].
2.5. Interaction between iron and adipocytes
Several recent studies have attempted to illuminate the effect of iron overload on adipocyte 
function. Although inflammatory cytokines can influence iron storage in various cell types, 
studies have shown that the link between elevated iron and obesity/diabetes is independent 
of inflammation [123, 124]. No central mechanism for the impact of iron on adipocytes is 
known; however, iron is known to influence adipocytes’ mitochondrial function and adipo-
nectin production [125]. Alterations in adipocyte mitochondrial iron content affect adipocyte 
differentiation and insulin sensitivity [126, 127]. Some studies have suggested that adipose 
tissue may be a primary target organ for the metabolic effects of iron. The results propose that 
stores of body iron and/or iron metabolism may be involved in the development of insulin 
resistance not only in liver or muscle but also in adipocytes [128]. Adipocytes require iron for 
normal function and differentiation. They also express specialized proteins involved in iron 
metabolism and this fact is well suited to possible adipocyte action as an iron sensor. Evidence 
that adipocyte iron levels regulate adiponectin transcription and serum protein levels is pres-
ent. These data further highlight the role of the adipocyte as a key regulator of metabolism 
in all tissues, based on integrated sensing of nutritional stores and iron availability [129]. The 
hypothesis that adiponectin links iron and insulin resistance is attractive as decreased adi-
ponectin levels are associated with insulin resistance during GDM, a relationship between 
its reduced concentration and β-cell dysfunction in GDM women [130]. Moreover, studies in 
mice, human, and cell culture have demonstrated that iron lowers adiponectin production and 
increases diabetes risk [129]. Serum ferritin levels, as indicator for tissue iron stores, reflect 
insulin resistance during diabetic pregnancy [131], with a higher level in GDM women in com-
parison to normal pregnant [132], and also with a risk of subsequent development of postpar-
tum impaired glucose tolerance and overt T2DM [131]. Furthermore, intracellular iron excess 
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catalyzes the formation of reactive oxygen species (ROS), promoting oxidative stress [133, 134] 
thus leading to increased β-cells apoptosis, hepatic dysfunction, and insulin resistance, and in 
consequence, promoting the T2DM progression [135]. Research data verify that serum ferritin 
concentrations are among the best predictors of serum leptin under physiological conditions. 
More importantly, the relationship is causal, reflecting regulation of leptin transcription by 
iron [136]. Studies on relationship between ferritin and leptin have suggested a possible link 
which is independent of relationship with BMI and inflammation. Iron overload may lead to 
a decrease in leptin serum level [137] along with the destruction of the fat cell membrane and 
the dysfunction in adipose tissue [138]. Opposite to this suggestion—leptin with other stimuli, 
such as pro-inflammatory cytokines, can be added to the list of adipose-derived factors that 
may contribute to hypoferremia observed in the overweight and obese population [139]. The 
functional significance of iron accumulation in adipocytes and the reduced leptin level is not 
yet clear. One possible explanation is that while iron regulates the serum leptin level, at the 
same time, it could have an effect on leptin signaling to a change in leptin sensitivity [140]. This 
interplay between iron, leptin, and adiponectin is an intriguing subject for study in various 
population groups, including pregnant women with gestational diabetes.
Deficiency of vitamin D is associated with impaired glucose homeostasis during pregnancy 
[141]. New studies underline the key role of vitamin D in glucose homeostasis and insulin 
resistance: 1,25(OH)2D3, the active form of vitamin D, regulates circulating glucose levels by 
binding to vitamin D receptor of pancreatic β-cell and modulating insulin secretion [142, 143]; 
it promotes insulin sensitivity by stimulating the expression of insulin receptors and enhancing 
insulin responsiveness for glucose transport [144]; regulates the balance between the extracel-
lular and intracellular calcium pools in pancreatic β-cell, [145]; it is responsible for the pres-
ence of vitamin response element in the human insulin gene promoter with stimulation of the 
expression of insulin receptor and for the effects on systemic inflammation by modulating the 
effects of cytokines on β-cell function [146], since insulin resistance and β-cell apoptosis could 
be induced by systemic inflammation. Vitamin D has a direct effect on pancreatic β-cells and 
is a prerequisite for the normal insulin secretion function of the endocrine pancreas [147, 148]. 
Probably, the active form of vitamin D decreases expression of pro-inflammatory cytokines 
such as IL-6, IL-1, and TNF-α involved in insulin resistance [149]. Some studies report a nega-
tive relationship between serum 25(OH) D levels, BMI [150–152], and HOMA-IR [147, 152]. 
Maternal overweight and obesity are among the highest modifiable risk factors. The preva-
lence of obesity is increasing, especially in women at reproductive age. In America, according 
to the data from Pregnancy Risk Assessment Monitoring System (PRAMS), one in five women 
is obese when they become pregnant, which presents the increase of the obesity prevalence 
by 70% compared to the previous decade [153]. Obesity is a risk factor for the development 
of GDM [154], and increased BMI is associated with a greater frequency of complications in 
pregnancy, at birth and postpartum [155, 156]. The most commonly studied index, body mass 
index, calculated by formula BMI = weight (kg)/height (m2) [37], is for measure of total body 
fat [157]. BMI is derived from easy measurements of height and weight and it is not expensive. 
Usually, women are classified as underweight (BMI less than 18.5), normal weight (BMI 18.5–
24.9), overweight (BMI 25.0–29.9), class I obese (BMI 30.0–34.9), class II obese (BMI 35–39.9), or 
class III obese (BMI 40.0 or greater), according to Institute of Medicine (IOM) [158]. There are 
some limitations maybe even more important when attempting to compare individuals from 
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different ethnic groups. The proposed BMI cut-off points ranging from 18·3 to 29·7 kg/m2 for 
children and adolescents aged 5–19 years, which correspond to the adult obesity threshold of 
30 kg/m2.These cut-offs are on the base of data from the USA population [159]. The use of these 
global cut-off points to define overweight and obesity remains contentious. Given the marked 
variations in different world regions, countries, and populations within countries, the use of 
these values may underestimate the health hazards of adult obesity [160]. Current studies 
show that maybe visceral fat mass is a novel risk factor for predicting gestational diabetes in 
obese pregnant women [161]. Central obesity as assessed by early pregnancy waist-hip ratio 
(WHR) and visceral fat mass (VFM) measured by bioimpedance is an independent predictor 
of GDM in addition to classical risk factors [162]. In a prospective study of 485 women cohort 
in Canada, elevated first trimester visceral and total adipose tissue depth independently pre-
dict the risk of subsequent dysglycemia in pregnancy [163]. Measures of central/abdominal 
obesity such as WC and WHR have been compared to BMI for their association with adverse 
cardiovascular and metabolic consequences [164]. BMI and WHR are significant risk factors 
for development of gestational diabetes and IR, but this association varies among different 
ethnicities [165]. Results of meta-analysis of 20 studies show that the risk of developing GDM 
is about two, four, and eight times higher among overweight, obese, or severely obese com-
pared with normal-weight women at the beginning of their pregnancies [166].
For every 1 kg/m2 increase in BMI, the prevalence of GDM increases by 0.92% [42]. The increas-
ing BMI index with 1 kg/m2 increased the risk of GDM developing with 9.9% [167] Increasing 
trend in the risk of severe adverse obstetric outcomes, rising along with increasing maternal 
BMI, exists [168]. Maternal overweight and obesity, diabetes, and excessive gestational weight 
gain are associated with fetal overgrowth and large for gestational age (LGA), which then 
can lead to an increased risk in the offspring for later obesity and diabetes [169, 170]. It has 
been found that in Finnish obstetric population, the maternal morbidity rises markedly when 
comparing overweight (BMI ≥26–29 kg/m2) vs. obese (BMI ≥ 30 kg/m2) women: the incidence 
of maternal diabetes, hypertension, and other chronic diseases [171].
3. Insulin resistance and insulin sensitivity in normal and GDM 
pregnancy
Pregnancy is a normal physiological state of insulin resistance, and it presents a physiologi-
cal stress model of pancreatic β-cells [172, 173]. It is associated with a decrease in insulin 
sensitivity of an approximate 50–60% by the latter half of pregnancy and a 200–250% increase 
in insulin secretion with purpose to maintain euglycemia in the mother [10]. The increased 
resistance is caused by post-insulin receptor events and is brought about by the cellular effects 
of the increased levels of some pregnancy-associated hormones [174]. In gestational diabetes, 
insulin resistance is not adequately compensated by insulin hypersecretion because of defec-
tive β-cell function. Insulin resistance during pregnancy reveals limitations in insulin secre-
tion; on the other hand, increasing insulin resistance and subsequent insulin hypersecretion 
may worsen the level of β-cell failure [174]. As a result, pregnant women with GDM have a 
higher level of insulin resistance compared to healthy pregnant women.
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Some studies demonstrate that the insulin secretion and sensitivity capacities of Asian women 
are different from those of women in Western countries. Since even in Asians, the pancreatic 
β-cell mass is relatively smaller than in Westerners, and insulin secretion capacity is also lower 
on the background of abdominal obesity is more common in Asians than in Westerners with 
similar body weights [175]. A study assesses the change in insulin resistance and β-cell function 
in a multiethnic population-based cohort of pregnant women. Pregnant women from East Asia 
and South Asia are more insulin resistant and show poorer β-cell function (HOMA-β) than 
Western Europeans [176]. The mechanisms leading to increased insulin secretion in pregnancy, 
primary or compensatory to resistance, are not entirely elucidated yet. They are partly related to 
metabolic effects of several hormones and cytokines which are elevated in maternal circulation 
during pregnancy [177]. Decreased insulin sensitivity or increased insulin resistance is defined 
as the decreased biological response of a nutrient to a given concentration of insulin at the target 
tissue, e.g., liver, muscle, or adipose tissue. Obesity is the most common risk factor related to 
decreased insulin sensitivity. During the pregnancy, it is related with maternal energy metabo-
lism, and visceral fat accumulation has important biological meaning. In this relation, the influ-
ence of visceral fat, respectfully BMI, and insulin sensitivity are too important [178].
In healthy pregnant women, pancreatic β-cells increase their insulin production through 
hyperplasia, hypertrophy, and hyperfunction to compensate for the pregnancy-induced insu-
lin resistance [176]. Maternal islets adapt to this increased demand mainly through enhanced 
insulin secretion per β-cell and increased β-cell proliferation [179]. Like other forms of hyper-
glycemia, GDM is characterized by pancreatic β-cell dysfunction that is insufficient to meet 
the body’s insulin needs. Available data suggest that β-cell defects in GDM are a result from 
the same spectrum of causes that underlie hyperglycemia in general, including autoimmune 
disease, monogenic causes, and insulin resistance [180]. In normal pregnancies, the dynamic 
changes in glucose homeostasis and insulin sensitivity are in connection with alterations in 
lipid and protein metabolism. Longitudinal studies of glucose tolerance during gestation 
demonstrate an increased insulin response to oral glucose in the first trimester relative to 
prepregnancy values [10], with a subsequent progressive increased insulin responses in con-
sistent with progressive IR [10]. Remarkably, there is an independent effect of pregnancy on 
β-cell function independent of the observed changes in insulin; but the etiology of this effect 
is at present unknown, although may include the role of incretins [181, 182]. The impact of 
obesity on these changes is significant; in particular, the decline in fasting glucose at early ges-
tation is reduced, but not reduced at all in severely obese women [183]. In late gestation, the 
normal reduction in peripheral insulin sensitivity of 50% is reduced in obese women [10]. In 
addition to significant peripheral and hepatic insulin resistance, which manifests as reduced 
insulin-mediated glucose disposal, there is a large reduction in insulin-stimulated carbohy-
drate oxidation and a reduction in insulin suppression of endogenous glucose production, all 
of which are reversed in the postpartum period [184]. Importantly, the overall effects of this 
impaired insulin resistance are not influenced only on the glucose. In the postprandial state, 
this obesity-related insulin resistance overacts the normal circulatory increases in metabolic 
fuels, i.e., glucose, lipids, and amino acids. The fasting, postprandial, and integrated 24-h 
plasma concentrations of all basic macronutrients are affected by enhanced insulin resistance 
in obese pregnant women [185].
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3.1. Homeostasis model assessment of insulin resistance (HOMA-IR)
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance 
and β-cell function, based on a single measurement of fasting glucose and insulin or C-peptide 
concentrations in the blood [186]. The easiest and most popular assessment of β-cell function 
is the homeostatic index HOMA-B. It is widely used because of its simplicity and it reflects 
the release of insulin under nonstimulated conditions [187]. HOMA model is considered as 
a structural model of the underlying physiological basis for the feedback loop between the 
liver and the β-cell in fasting [188]. HOMA-IR has been observed to have a linear correlation 
with the glucose clamp and considered as minimal model for estimations of insulin sensitiv-
ity/resistance in various studies [188, 189]. HOMA-IR determines the relationship between 
the liver and pancreas. This index reflects more the liver insulin resistance in comparison to 
peripheral insulin resistance [190], and it is a good indicator of overall insulin sensitivity dur-
ing pregnancy. Although surrogate marker HOMA-B is less evaluated as an index, it provides 
high reliability in the measurement of β-cell function. Both indices, HOMA-B and HOMA-IR, 
submit better overall picture of the essential metabolic disorder [191]. Disadvantage of HOMA 
model is related to the fact that it underlines the lack of linearity at deepening of insulin 
resistance [192]. This model is a widely used and well correlates with the insulin sensitivity, 
as measured by the venous clamp technique in various studies [188, 189].
3.2. Assessment of insulin sensitivity by using quantitative insulin sensitivity check 
index (QUICKI) and HOMA2 variant insulin sensitivity (HOMA %S)
The quantitative insulin sensitivity check index (QUICKI) is an empirically derived math-
ematical transformation of fasting blood glucose and plasma insulin concentrations [193, 194]. 
QUICKI is a simple, robust, accurate, and reproducible method that appropriately predicts 
changes in insulin sensitivity after therapeutic interventions as well as the onset of diabetes 
[195]. QUICKI has been seen to have a significantly better linear correlation with glucose 
clamp determinations of insulin sensitivity than minimal-model estimates [196]. Its calcula-
tion is used to evaluate the insulin sensitivity [197] including during early and late pregnancy 
[190]. The index assumes that the circulating glucose and insulin are determined by a feed-
back loop between the liver and pancreatic β-cells [198]. Insulin sensitivity has been modeled 
by proportionately decreasing the effect of plasma insulin concentrations at both the liver and 
the periphery [199]. Other parameter to assess insulin sensitivity is HOMA-S%. The computer 
model can be used to determine insulin sensitivity (HOMA–S%) from paired fasting plasma 
glucose and insulin concentrations. The data from individual subjects determine unique com-
binations of insulin sensitivity (HOMA %S) and beta cell function (HOMA %B) from steady-
state conditions [200]. HOMA can be used to track changes in insulin sensitivity and β-cell 
function in individuals. Also, it can be used in individuals to indicate whether reduced insulin 
sensitivity or β-cell failure predominates. Determination of HOMA-%S is used to establish 
the prevailing normal over a normoglycemic population in each comparative group [188]. 
Maternal obesity is associated with higher maternal glucose and GDM risk; its association 
with newborn size at birth is, in part, independent of maternal glycemia [201–204]. BMI is an 
indicator of the tissue quantity (weight) over the skeletal frame (height), including adipose 
tissue and muscle. BMI is known to increase blood volume and to reduce the concentration 
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of serum metal ions, such as, iron and zinc [205]. Maternal overweight (BMI ≥ 25 kg/m2) has 
been shown to be the strongest risk factor for GDM. Two meta-regression analyses show that 
the odds ratios for developing GDM are 1.97–2.14 in overweight (BMI ≥ 25 kg/m2), 3.01–3.56 in 
obese (most studies BMI ≥ 30 kg/m2), and 5.55–8.56 in severely obese (BMI ≥ 35–45 kg/m2) 
women compared with normal weight women [154].
3.3. The effect of BMI on insulin sensitivity indices
In late gestation, the normal reduction in peripheral insulin sensitivity of 50% [206] is reduced 
in obese women as determined by the quantitative insulin sensitivity check index and that 
insulin sensitivity in women with GDM worsened as gestation progressed [207]. The indexes 
of insulin sensitivity QUICKI and HOMA significantly correlated with a direct measurement 
of insulin sensitivity using the euglycemic-hyperinsulinemic clamp during pregnancy [208]. 
The mechanism for the decrease in insulin sensitivity in pregnancy is not fully understood 
and is part of the natural process during pregnancy, although the insulin signaling pathway 
can be interrupted by several factors, such as increased levels of serum cortisol, TNF α, and 
some interleukin cytokines, leading to insulin resistance, during normal pregnancy [104]. In 
this connection, it would appear that preconceptual fat mass is one of a major determinant, 
because lean women exhibit an inverse correlation between changes in insulin sensitivity and 
fat mass, which is not seen in obese women [209]. Obese women exhibit a negative relation-
ship between the decrease in insulin sensitivity and accretion of fat mass from prepregnancy 
to late gestation [210]. Visceral fat volume in human body has important biological mean-
ing, which is well expressed during the pregnancy. In this relation, the influence of visceral 
fat, respectfully BMI, on the insulin sensitivity is too important. A study has announced 
diminished insulin sensitivity in pregnant women with GDM compared to healthy pregnant 
women for BMI (P > 0.05) with significantly higher body fat percentage, expressed by connec-
tion QUICKI index-BMI (r = −0.384, P < 0.01) [211]. These results are similar to other author′s 
results—lower level of insulin sensitivity index QUICKI in pregnant women with GDM in 
comparison to NGT Р = 0.001, a reverse correlation between QUICKI index and BMI in the 
both of group (r = −0.458 for NGT and r = −0.603 for GDM) [167]. Insulin sensitivity measured 
during the clamp was higher during pregnancy in the NGT group than in the GDM group 
(P < 0.05) [208]. Values of QUICKI index in overweight women with normal glucose toler-
ance (NGT) and in women with GDM have been significantly lower (P < 0.01) than those in 
normal-weight women with NGT, and QUICKI in women with GDM has been decreased 
significantly (P < 0.05) during pregnancy, according to Endo et al. [207]. Furthermore, other 
authors have reported significant interaction between race and BMI (under/normal weight, 
overweight/obese) for glucose, insulin, and HOMA-IR at or above the 75th percentile and 
QUICKI less than the 25th percentile in mid-trimester [212]. Other authors have detected 
lower levels of QUICKI index in overweight compared to normal-weight women at third 
trimester of pregnancy [199]. Changes in insulin sensitivity are a hallmark of pregnancy and 
contribute to the metabolic changes, while nutrient transfer to the fetus impacts maternal 
metabolite levels [213, 214]. Studies show that values for HOMA-S% between pregnant with 
GDM and matched control NGT subject are highly significant different (P < 0.001) [215, 
216]. Some authors found lower level for HOMA S% in GDM pregnant with prepregnancy 
BMI ≥ 25 kg/m2 in comparison to GDM with prepregnancy BMI <25 kg/m2 (P < 0.001) [217]. 
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These values are not markedly different from those obtained in the other study [167]. In this 
study, there are statistically significant differences in HOMA-S% between the NGT and GDM 
groups (Р = 0.002). It is found a reverse correlation between HOMA-S% and BMI in the both 
NGT and GDM patient groups (r = −0.467 and r = −0.679, respectively). The authors’ hypoth-
esis is that as higher is a BMI, stronger is its influence on insulin sensitivity, expressed by 
HOMA-S% index [167]. The current studies confirm that GDM is associated with increased 
insulin resistance and β-cell dysfunction, as well as reduced insulin sensitivity and secretion.
BMI, glucose, and insulin sensitivity are interrelated and alter maternal metabolism. A novel 
aspect of studies is identification of metabolic signatures uniquely associated with maternal 
BMI and glycemia, including differences in metabolites most strongly associated with these 
phenotypes [218]. The association of several plasma metabolites with maternal prepreg-
nancy BMI across gestation in a cohort of 167 non-Hispanic and Hispanic ancestry women 
was reported [219]. Some of these metabolites have been found to have a role in aspects of 
metabolism such as insulin sensitivity and pancreatic β-cell function. A limited number of 
GDM metabolomics studies have been performed, evidence suggests that the metabolic sig-
natures of T2D and GDM overlap [220]. Metabolomic studies of maternal metabolism during 
pregnancy are focused largely on normal pregnancy and GDM [221–227]. It is important to 
examine the associations of maternal BMI on the maternal metabolome, to consider estimated 
maternal insulin sensitivity as a predictor of the maternal metabolome. Furthermore, mater-
nal BMI and insulin sensitivity impact a broad array of metabolites and have shared indepen-
dent associations with the maternal metabolome [228].
3.4. The effect of BMI on homeostasis model assessment of insulin resistance 
(HOMA-IR)
Insulin resistance is, by definition, a disorder in the signal transduction of several known 
hormones [229]. Insulin resistance in peripheral tissues in women with GDM is exacerbated, 
but few studies have examined the extent of insulin resistance in placenta in this disease. 
It is possible that this insulin resistance could contribute to alter the placental transport of 
nutrients [230–232]. The degree of maternal insulin resistance manifested during pregnancy is 
theoretically associated with the degree of glucose flux from mother to fetus. Excessive insulin 
resistance during pregnancy is also observed in obese subjects without abnormal glucose toler-
ance [10]. Different studies found HOMA-IR values in the GDM group are significantly higher 
than in NGT patients, which indicated a significant insulin resistance [167, 215, 233–239]. Some 
studies report controversial results. They found that the HOMA-IR values are similar in GDM 
patients and healthy NGT controls [240–243]. Women with GDM in early pregnancy had sig-
nificantly higher HOMA-IR values than those with GDM in later pregnancy or those with 
NGT [244] and results are similar to other from prior work [245]. Probably, higher BMIs among 
women with early-onset GDM are detected to at least partially explain this phenomenon [246]. 
An important goal is to identifying women with GDM during early pregnancy to minimize 
maternal and neonatal morbidity. One study reported that first trimester HOMA-IR values 
are independent predictors for the development of GDM in logistic regression analysis, and 
the HOMA-IR value is found to be a better marker (AUC ¼ 0.75; 95% CI, 0.67e0.83) than the 
other factors [247]. Another study detects borderline significance for risk of subsequent GDM 
for increased HOMA-IR values at gestational weeks 16–18, independent of other variables that 
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are associated with GDM [248]. Some researchers determined the predictability of GDM with 
a 90% sensitivity and 61% specificity by ROC analysis in patients whose HOMA-IR scores are 
>2.08 in the first trimester [249]. A study reports that HOMA-IR at 21–28 gestational weeks is 
reliable risky factor to development of IR (OR = 0.677, 95% CI = 0.573–0.781, P = 0.002, sensitiv-
ity 54.7%, and specificity 24.5%). HOMA-IR is found with statistically significant impact on 
developing of GDM-OR = 2.039 (95% CI = 1.427–2.914, P < 0.0001). The increasing HOMA-IR 
index with unit increases the risk of GDM developing about two times. The predictive thresh-
old values for developing insulin resistance in gestational pregnant at 21–28 gestational weeks 
are HOMA–IR > 1.8 [250]. According to the International Diabetes Federation (IDF) criteria, the 
HOMA-IR cut-off point to differentiate low and high value of insulin resistance is 2.38. Several 
previous studies performed on smaller populations have demonstrated that HOMA-IR index 
assessed at diagnosis of GDM is ranged from 1.6 to 25 [130, 176, 251, 252]. HOMA-IR values of 
≥1.29 at diagnosis may indicate insulin resistance in the studied population of women and are 
associated with a higher value of the prepregnancy BMI [177]. Maternal obesity-prepregnancy 
at the time of GDM diagnosis is in connection to enhance insulin resistance. A positive cor-
relation between BMI and HOMA-IR in NGT group r = 0.485 and in GDM pregnant r = 0.594 
has been established without statistical difference between two pregnant groups in second to 
third trimester [250]. The results are similar to those of others studies [253–255]. Other study 
obtains no significant correlations between BMI and markers of insulin resistance, indicating 
that BMI is not a confounder in the elevated insulin resistance among the enrolled GDM sub-
jects [256]. The correctness requires to be noted some authors refer to BMI, especially in preg-
nancy, to be a poor index of fat mass, and it could be superseded in the statistical models by 
other anthropometric measures, three of which were independent predictors of GDM. These 
simple measures (age, fasting blood glucose, and subcutaneous fat), while are recognized in 
a few earlier reports, they are largely ignored in assessment of GDM risk [257–259]. Other 
study finds trimester-specific strongly positive association between HOMA-IR and prepreg-
nancy BMI in each trimester (P < 0.001 in trimester 1 and 2, P = 0.004 in trimester 3). Also, the 
results from these analyses support the notion that the maternal metabolome is predominantly 
influenced by obesity and less by dietary intake during pregnancy [219]. However, it appears 
that beginning of the pregnancy in the obese state disturbs normal anabolic activity through 
early-gestational insulin resistance [260]. This may suggest that the obesity induces various 
metabolic and hormone fluctuations, rather than insulin resistance alone. This study demon-
strates for the first time an association between prepregnancy BMI and a pattern of metabolites 
related to obesity, which differs from nonpregnant cohorts [219].
4. Conclusions
Undoubtedly, in recent years, the frequency of GDM is increasing in tandem with the dramatic 
increase in the prevalence of overweight and obesity in women of childbearing age, assessing by 
BMI. Another risk factor for GDM is the excessive weight gain during the pregnancy, assessing 
by use of BMI. The optimal weight increase in pregnancy is well established on the base of stud-
ies, and is different depending on BMI prior to pregnancy. Some studies show, that excessive 
weight gain is a significant risk factor for GDM in all categories of BMI, but the relationship is 
more stringent in obese individuals. Most of studies observed that higher BMI decreases the 
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insulin sensitivity, increases the IR and contributes to development of GDM. New guidelines 
into the mechanisms underlying maternal metabolism during pregnancy are being gained 
through the use of new technologies. Future studies on the base of integrated data from multiple 
technologies will allow a systems biology approach to maternal metabolism during pregnancy.
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